Preclinical CBG study reports short-lived blood-pressure and platelet effects

CBG lowered systolic pressure by 18% after a single intravenous dose in hypertensive rats and inhibited platelet activity in laboratory tests using human blood samples. Oklahoma product teams should view the findings as early-stage cardiovascular research, not a marketing claim, because dosing was intravenous, effects were brief, and human safety and bleeding risks remain untested.